SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
-20.94%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$803M
AUM Growth
+$803M
(-28%)
Cap. Flow
-$45.5M
Cap. Flow
% of AUM
-5.67%
Top 10 Holdings %
Top 10 Hldgs %
60.78%
Holding
77
New
17
Increased
17
Reduced
13
Closed
18
Top Buys
| 1 |
NCNA
NuCana
NCNA
|
$23.2M |
| 2 |
Gilead Sciences
GILD
|
$13.3M |
| 3 |
Incyte
INCY
|
$12M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$12M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$8.86M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$61.5M |
| 2 |
AGN
Allergan plc
AGN
|
$18.3M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$9.09M |
| 4 |
Exelixis
EXEL
|
$7.15M |
| 5 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$6.92M |
Sector Composition
| 1 | Healthcare | 91.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $93.9M | 11.7% | 1,498,538 -980,976 | -40% | -$61.5M |
|
|
AMRN
2
Amarin Corp
AMRN
$311M
| $70.9M | 8.83% | 5,208,305 -1 | -0% | -$14 |
|
|
OBSV
3
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $60.1M | 7.49% | 4,749,623 | – | – |
|
|
PRNB
4
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $55.8M | 6.95% | 2,038,208 -20,938 | -1% | -$573K |
|
5
Natera
NTRA
$23.1B
| $43.3M | 5.39% | 3,100,560 | – | – |
|
6
Y-mAbs Therapeutics
YMAB
$388M
| $42.8M | 5.33% | 2,104,278 | – | – |
|
|
NCNA
7
NuCana
NCNA
$6.09M
| $32.9M | 4.09% | 2,266,666 +1,600,000 | +240% | +$23.2M |
|
8
Merus
MRUS
$4.98B
| $27.5M | 3.42% | 1,961,039 | – | – |
|
9
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $26M | 3.23% | 2,868,221 | – | – |
|
10
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $25.9M | 3.23% | 922,700 | – | – |
|
|
BOLD
11
DELISTED
Audentes Therapeutics, Inc
BOLD
| $19.9M | 2.48% | 933,640 | – | – |
|
|
ONCE
12
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $18.8M | 2.35% | 481,270 | – | – |
|
13
Sanofi
SNY
$121B
| $14.2M | 1.77% | 327,175 -85,571 | -21% | -$3.71M |
|
14
Aclaris Therapeutics
ACRS
$209M
| $14.1M | 1.76% | 1,911,573 +372,093 | +24% | +$2.75M |
|
|
15
Gilead Sciences
GILD
$140B
| $13.3M | 1.66% | +213,331 | New | +$13.3M |
|
16
AstraZeneca
AZN
$248B
| $12M | 1.5% | 316,328 +75,720 | +31% | +$2.88M |
|
|
17
Incyte
INCY
$16.5B
| $12M | 1.49% | +188,497 | New | +$12M |
|
|
18
BioMarin Pharmaceuticals
BMRN
$11.2B
| $12M | 1.49% | +140,542 | New | +$12M |
|
|
TSRO
19
DELISTED
TESARO, Inc.
TSRO
| $9.97M | 1.24% | 134,297 -89,378 | -40% | -$6.64M |
|
20
Heron Therapeutics
HRTX
$207M
| $9.33M | 1.16% | 359,713 +64,124 | +22% | +$1.66M |
|
|
RETA
21
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $8.86M | 1.1% | +157,984 | New | +$8.86M |
|
22
Iterum Therapeutics
ITRM
$30.2M
| $8.65M | 1.08% | 1,726,514 | – | – |
|
23
Rigel Pharmaceuticals
RIGL
$697M
| $7.78M | 0.97% | 3,382,174 +121,243 | +4% | +$279K |
|
24
Xencor
XNCR
$580M
| $7.22M | 0.9% | +199,682 | New | +$7.22M |
|
25
Amicus Therapeutics
FOLD
$2.34B
| $6.46M | 0.81% | 674,636 +228,667 | +51% | +$2.19M |
|